Faslodex combo approved by FDA | Celgene MS drug promising in late-stage trials | Case study finds voxelotor beneficial to patient with sickle cell disease
November 16, 2017
Bio SmartBrief
Today's Top Story
Faslodex combo approved by FDA
The FDA approved AstraZeneca's Faslodex in combination with the CDK4/6 inhibitor abemaciclib to treat hormone receptor-positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer following endocrine therapy.
PharmaTimes (U.K.) (11/15) 
LinkedIn Twitter Facebook Google+ Email
Your Oncology RFP Planning Guide is Ready!
Explore key cost drivers for oncology studies, such as: impact of geography, uncovering project management variations, and how timeline impacts cost savings. Download this complimentary eBook from Novella Clinical: RFP Guide to Oncology Clinical Trials.
Health Care & Policy
Celgene MS drug promising in late-stage trials
Relapsing multiple sclerosis patients taking Celgene's ozanimod showed lower rates of relapse and fewer MRI brain lesions than those taking Avonex, or interferon beta-1a, according to two late-stage trials. Celgene plans to file a new drug application for the therapy.
Multiple Sclerosis News Today (11/15) 
LinkedIn Twitter Facebook Google+ Email
Case study finds voxelotor beneficial to patient with sickle cell disease
A 67-year-old male patient experiencing severe, transfusion-refractory anemia was given compassionate access to the late-stage HOPE trial for Global Blood Therapeutics' candidate voxelotor and showed significant improvement in hemoglobin levels, fatigue, pain and overall mental health after two weeks of receiving a once-daily, 900-mg oral dose of the drug. The details of the case study were presented at the annual convention of the Sickle Cell Disease Association of America.
Sickle Cell Anemia News (11/14) 
LinkedIn Twitter Facebook Google+ Email
EMA grants PRIME status to Mereo's brittle bone drug
The European Medicines Agency accepted into its PRIME priority medicines program Mereo BioPharma's brittle bone disease drug candidate BPS-804, which will fast-track the drug's review process in Europe. The drug is being assessed in a Phase IIb osteoporosis imperfecta trial.
PharmaTimes (U.K.) (11/14) 
LinkedIn Twitter Facebook Google+ Email
EU approves Boehringer Ingelheim's biosimilar version of Humira
Boehringer Ingelheim's Cyltezo, or adalimumab, a biosimilar version of AbbVie's Humira, was granted European approval to treat inflammatory diseases including Crohn's disease, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis. A comprehensive data package comprising analytical, pharmacological, nonclinical and clinical data supported the biosimilarity of Cyltezo to Humira.
PharmaTimes (U.K.) (11/14) 
LinkedIn Twitter Facebook Google+ Email
Company & Financial News
Genmab gains $25M milestone payment from sale of myeloma drug in Japan
The first commercial sale of the multiple myeloma drug Darzalex, or daratumumab, by Janssen Biotech in Japan will trigger a $25 million milestone payment to Genmab. The payment is part of a global licensing and development agreement for Darzalex that the firms completed in August 2012.
Seeking Alpha (free registration) (11/14) 
LinkedIn Twitter Facebook Google+ Email
Funding round raises $19M for Locus to develop CRISPR-Cas3 technology
Locus Biosciences plans to use the $19 million it raised from a Series A funding round to develop antimicrobials to combat drug-resistant bacteria such as Clostridium difficile, Pseudomonas aeruginosa and Enterobacteriaceae. The company is using CRISPR-Cas3, a variant of CRISPR-Cas9, to destroy the target bacteria's DNA while sparing beneficial bacteria.
WRAL TechWire (Raleigh, N.C.) (11/15) 
LinkedIn Twitter Facebook Google+ Email
The Latest From BIO ...
Learn more about key policy issues affecting biotechnology in Washington, D.C., and state capitals around the country. With the unpredictability of the federal level coupled with the increasingly hostile state legislatures, it is vital that the biotechnology industry amplify its voice on the federal, state and local levels. Become an advocate for biotechnology by joining BIO Action today. Now, more than ever, we need your voice! Text BIO to 52886 or visit BIO's website.
LinkedIn Twitter Facebook Google+ Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
Industry Deals
Genentech expands PROTAC deal with Arvinas
Roche Holding unit Genentech acquired a license to develop new drugs using Arvinas' Proteolysis Targeting Chimeras platform, expanding the companies' 2015 agreement. The deal grants Arvinas more than $650 million in milestones, an increase from $300 million in the original agreement, plus tiered royalties.
BioCentury (11/15) 
LinkedIn Twitter Facebook Google+ Email
Food & Agriculture
Economist: US doubles food production with biotech crops
Montana economist Gary Brester said at the Montana Farm Bureau Federation convention that US farmers have been producing two times as much food per acre now than they did 60 years ago by growing biotech crops. Despite the increased rate of food production, farmers still use the same amount of fertilizer and other growth enhancers as they did years ago, Brester said.
Billings Gazette (Mont.) (11/14) 
LinkedIn Twitter Facebook Google+ Email
Industrial & Environmental
EIA releases US ethanol production forecasts for 2017, 2018
Ethanol production in the US is predicted to average 1.03 million barrels per day in 2017, increasing to 1.04 million barrels per day in 2018, according to the November edition of the Energy Information Administration's Short-Term Energy Outlook. Meanwhile, production of ethanol averaged 1.057 million barrels per day for the week ending Nov. 3, up from 1.056 million barrels per day from the week before.
Ethanol Producer Magazine online (11/13) 
LinkedIn Twitter Facebook Google+ Email
IKEA partnership to turn food waste into biogas
IKEA Finland is teaming up with energy company Gasum to convert food waste from IKEA stores into biogas to fuel vehicles. Gasum will install filling stations at IKEA locations in Finland as part of the agreement.
Innovators (UK) (10/11) 
LinkedIn Twitter Facebook Google+ Email
News From BIO
All the tools you need to communicate your financial news
Business Wire provides all the tools needed to quickly, broadly and effectively communicate your news to investors, analysts, the media and other audiences. Filing an IPO and taking your company public is a long process that requires a comprehensive communications plan. BIO has aligned with Business Wire to help you effectively distribute your news releases at preferred pricing. Business Wire provides all the tools you need to quickly and broadly communicate your news to investors, analysts, the media and other audiences. Learn how we can help.
LinkedIn Twitter Facebook Google+ Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
Press Releases
Post a Press Release
The risk is the challenge.
Mario Andretti,
auto racer
The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.
Sign Up
SmartBrief offers 200+ newsletters
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Nicole Brown
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information